29th Jan 2019 15:40
LONDON (Alliance News) - Omega Diagnostics Group PLC said Tuesday it has successfully manufactured three validation batches of its Visitect CD4 Advanced Disease test.
The finished devices were tested in India, Zimbabwe and the UK and results demonstrate that all three batches performed in line with the company's design goal parameters.
"These validation batches prove we can manufacture at scale and are a requirement for obtaining a CE Mark," Omega said.
Omega shares were trading up 3.1% at 13.66 pence each.
Related Shares:
ODX.L